Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Glatiramer acetate 40mg/1ml inj pre-filled syringes
0802040U0AAACAC
|
Glatiramer acetate | Glatiramer acetate | Malignant Disease and Immunosuppression | No data available |
|
Gliadel 7.7mg implant
0801010D0BCAAAB
|
Gliadel | Carmustine | Malignant Disease and Immunosuppression | No data available |
|
Glivec 100mg capsules
0801050AABBAAAA
|
Glivec | Imatinib mesilate | Malignant Disease and Immunosuppression | No data available |
|
Glivec 100mg tablets
0801050AABBACAC
|
Glivec | Imatinib mesilate | Malignant Disease and Immunosuppression | No data available |
|
Glivec 400mg tablets
0801050AABBABAB
|
Glivec | Imatinib mesilate | Malignant Disease and Immunosuppression | No data available |
|
Halaven 0.88mg/2ml solution for injection vials
0801050BBBBAAAA
|
Halaven | Eribulin | Malignant Disease and Immunosuppression | No data available |
|
Halaven 1.32mg/3ml solution for injection vials
0801050BBBBABAB
|
Halaven | Eribulin | Malignant Disease and Immunosuppression | No data available |
|
Herceptin 150mg pdr for concentrate for inf vials
0801050ADBBAAAA
|
Herceptin | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Herceptin 600mg/5ml solution for injection vials
0801050ADBBABAB
|
Herceptin | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Herzuma 150mg pdr for concentrate for inf vials
0801050ADBEAAAA
|
Herzuma | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Herzuma 420mg pdr for concentrate for inf vials
0801050ADBEABAE
|
Herzuma | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Histamine dihydrochloride 500micrograms/0.5ml inj vials
0802040ABAAAAAA
|
Histamine dihydrochloride | Histamine dihydrocloride | Malignant Disease and Immunosuppression | No data available |
|
Histrelin 50mg implant with device
0803042Q0AAAAAA
|
Histrelin acetate | Histrelin acetate | Malignant Disease and Immunosuppression | No data available |
|
Honvan 120mg tablets
0803010D0BBADAD
|
Honvan | Fosfestrol tetrasodium | Malignant Disease and Immunosuppression | No data available |
|
Honvan 300mg/5ml solution for injection ampoules
0803010D0BBACAC
|
Honvan | Fosfestrol tetrasodium | Malignant Disease and Immunosuppression | No data available |
|
Hycamtin 0.25mg capsules
0801050AFBBACAC
|
Hycamtin | Topotecan | Malignant Disease and Immunosuppression | No data available |
|
Hycamtin 1mg capsules
0801050AFBBADAD
|
Hycamtin | Topotecan | Malignant Disease and Immunosuppression | No data available |
|
Hycamtin 1mg pdr for concentrate for inf vials
0801050AFBBAAAA
|
Hycamtin | Topotecan | Malignant Disease and Immunosuppression | No data available |
|
Hycamtin 4mg pdr for concentrate for inf vials
0801050AFBBABAB
|
Hycamtin | Topotecan | Malignant Disease and Immunosuppression | No data available |
|
Hydroxycarbamide 300mg capsules
0801050P0AAACAC
|
Hydroxycarbamide | Hydroxycarbamide | Malignant Disease and Immunosuppression | No data available |
|
Hyftor 2mg/g gel
0802020U0BCAAAG
|
Hyftor | Sirolimus | Malignant Disease and Immunosuppression | No data available |
|
Ibrance 100mg capsules
0801050CBBBABAB
|
Ibrance | Palbociclib | Malignant Disease and Immunosuppression | No data available |
|
Ibrance 100mg tablets
0801050CBBBADAD
|
Ibrance | Palbociclib | Malignant Disease and Immunosuppression | No data available |
|
Ibrance 125mg capsules
0801050CBBBACAC
|
Ibrance | Palbociclib | Malignant Disease and Immunosuppression | No data available |
|
Ibrance 125mg tablets
0801050CBBBAEAE
|
Ibrance | Palbociclib | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.